Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors

被引：0

作者：

Kefford, Richard

Miller, Wilson H.

Tan, Daniel Shao-Weng

Sullivan, Ryan J.

Long, Georgina

Dienstmann, Rodrigo

Tai, Wai Meng David

Flaherty, Keith

Stutvoet, Simone

Schumacher, Karl Maria

Wandel, Simon

De Parseval, Laure A.

Tabernero, Josep

机构：

[1] Univ Sydney, Westmead Inst Canc Res, Melanoma Inst Australia, Sydney, NSW 2006, Australia

[2] Univ Sydney, Westmead Hosp, Sydney, NSW 2006, Australia

[3] McGill Univ, Jewish Gen Hosp, Lady Davis Inst, Montreal, PQ H3T 1E2, Canada

[4] McGill Univ, Jewish Gen Hosp, Segal Canc Ctr, Montreal, PQ H3T 1E2, Canada

[5] Natl Canc Ctr, Singapore, Singapore

[6] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[7] Univ Sydney, Westmead Hosp, Melanoma Inst Australia, Sydney, NSW 2006, Australia

[8] Vall dHebron Inst Oncol, Barcelona, Spain

[9] Natl Canc Ctr Singapore, Singapore, Singapore

[10] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA

[11] Novartis Pharma AG, Basel, Switzerland

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9029

引用

页数：1

共 50 条

[1] Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results
Richard Kefford
Ryan J Sullivan
Wilson H Miller
Elena M Elez
Daniel Tan
Kevin B Kim
Georgina V Long
Keith T Flaherty
David Tai
Simone Stutvoet
Heiko Maacke
Matt Whiley
Laure Moutouh-de Parseval
Josep Tabernero
Journal of Translational Medicine, 12 (Suppl 1)
[2] Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma
Dummer, Reinhard
Robert, Caroline
Nyakas, Marta
McArthur, Grant A.
Kudchadkar, Ragini Reiney
Gomez-Roca, Carlos
Sullivan, Ryan J.
Flaherty, Keith
Murer, Carla
Michel, Daniela
Tang, Zhongwen
De Parseval, Laure A.
Delord, Jean-Pierre
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[3] A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor
Johanna C Bendell
Milind Javle
Tanios S Bekaii-Saab
Richard S Finn
Zev A Wainberg
Daniel A Laheru
Colin D Weekes
Benjamin R Tan
Gazala N Khan
Mark M Zalupski
Jeffrey R Infante
Suzanne Jones
Kyriakos P Papadopoulos
Anthony W Tolcher
Renae E Chavira
Janna L Christy-Bittel
Emma Barrett
Amita Patnaik
British Journal of Cancer, 2017, 116 : 575 - 583
[4] A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor
Bendell, Johanna C.
Javle, Milind
Bekaii-Saab, Tanios S.
Finn, Richard S.
Wainberg, Zev A.
Laheru, Daniel A.
Weekes, Colin D.
Tan, Benjamin R.
Khan, Gazala N.
Zalupski, Mark M.
Infante, Jeffrey R.
Jones, Suzanne
Papadopoulos, Kyriakos P.
Tolcher, Anthony W.
Chavira, Renae E.
Christy-Bittel, Janna L.
Barrett, Emma
Patnaik, Amita
BRITISH JOURNAL OF CANCER, 2017, 116 (05) : 575 - 583
[5] Results of a phase 1 study of MEK162, an oral MEK inhibitor, in Japanese patients with advanced solid tumors
Shimokata, T.
Watanabe, K.
Shibata, T.
Inada-Inoue, M.
Shirao, K.
Hirashima, Y.
Fukuhara, S.
Tokushige, K.
Zubel, A.
Ando, Y.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S870 - S871
[6] Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors
Tolcher, Anthony W.
Kurzrock, Razelle
Valero, Vincente
Gonzalez, Rene
Heist, Rebecca S.
Tan, Antoinette R.
Means-Powell, Julie
Werner, Theresa L.
Becerra, Carlos
Wang, Chenxi
Leonowens, Cathrine
Kalyana-Sundaram, Shanker
Kleha, Joseph F.
Gauvin, Jennifer
D'Amelio, Anthony M.
Ellis, Catherine
Ibrahim, Nageatte
Yan, Li
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (04) : 673 - 683
[7] Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors
Anthony W. Tolcher
Razelle Kurzrock
Vincente Valero
Rene Gonzalez
Rebecca S. Heist
Antoinette R. Tan
Julie Means-Powell
Theresa L. Werner
Carlos Becerra
Chenxi Wang
Cathrine Leonowens
Shanker Kalyana-Sundaram
Joseph F. Kleha
Jennifer Gauvin
Anthony M. D’Amelio
Catherine Ellis
Nageatte Ibrahim
Li Yan
Cancer Chemotherapy and Pharmacology, 2020, 85 : 673 - 683
[8] A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
Pacey, S.
Blackhall, F.
Garcia-Corbacho, J.
Lipplaa, A.
Fusi, A.
Kumar, S.
Hategan, M.
Derham, J.
Laviste, G.
Halford, S.
Foxton, C.
McLeod, R.
Wan, S.
Talbot, D.
ANNALS OF ONCOLOGY, 2016, 27
[9] A phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with BRAF V600-mutant solid tumors and melanoma.
Ascierto, Paolo Antonio
Bechter, Oliver
Wolter, Pascal
Lebbe, Celeste
Elez, Elena
Miller, Wilson H.
Long, Georgina V.
Omlin, Aurelius Gabriel
Siena, Salvatore
Calvo, Emiliano
Pickard, Mike
Gollerkeri, Ashwin
Wollenberg, Lance
Germa, Caroline
Dummer, Reinhard
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[10] A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors.
Bedard, Philippe
Tabernero, Josep
Kurzrock, Razelle
Britten, Carolyn D.
Stathis, Anastasios
Manuel Perez-Garcia, Jose
Zubel, Angela
Le, Ngocdiep T.
Carter, Kirsten
Bellew, Kevin M.
Gallarati, Chiara
Niazi, Faiz
Demanse, David
De Buck, Stefan S.
Sessa, Cristiana
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →